Video
Oral testosterone undecanoate shows promising results for first use in the real world
Author(s):
“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.
In this video, Jay Newmark, MD, MBA, discusses the background, findings, and takeaways of the study, “Real-World Experience with First FDA-Approved Oral Testosterone Undecanoate Formulation,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Newmark is a chief medical officer at Clarus Therapeutics, Northbrook, Illinois.
Related Videos
Related Content
